AUG 10, 2016 03:14 PM PDT

One Drug to Take Down 3 Deadly Parasites?

WRITTEN BY: Xuan Pham
Pharmaceutical giant Novartis announced drastic and fruitful measures to combat three killer parasites that affect millions of people worldwide. After screening a whopping 3 million chemical compounds, they landed on a single drug that can kill parasites causing sleeping sickness, Chagas disease, and Leishmaniasis.
 
"What makes it special is the fact it is targeting all three parasites. That's the first time it has been done, so it is quite special,” said Elmarie Myburgh, co-author of the study published as a Letter in Nature.
 
Worldwide, around 20 million people are affected with sleeping sickness (via Trypanosoma brucei), Chagas disease (via Trypansosoma cruzi), and Leishmaniasis (via Leishmania). All three parasites share similar biology and genomic sequence, which prompted the quest for a common drug.
 
Indeed, scientists from the Genomics Institute of the Novartis Research Foundation combed through 3 million compounds – no small feat by any stretch of the imagination. Their persistence paid off when they finally found one compound that killed multiple parasites in the lab. Known as GNF6702 for now, the drug targets the parasites’ proteasomes – structures that chew up and recycle damaged or waste proteins in the cells.
 
Even if it can kill all the parasites, a drug is no good if it also kills the host cells indiscriminately. Luckily, in experiments, the team showed the drug inhibits the parasites’ proteasomes without affecting those of mammalian cells.
 
With modifications, the drug was made even more potent – 20 times more potent to be exact. But this seemed to be tolerated with no problem in mice, giving hope that pre-clinical and clinical trials will also show promising results.
 

"To me this is obviously a big deal, I'm in this field to try and make a difference, to get to a cure, and we're working hard in the hope that it gets to patients,” said Myburgh. "There's been very little incentive to spend a lot of money on these diseases as they affect a very poor, and yet large, population."
 
Drugs that are available currently to combat these infections have big limitations. Chief among them are cost, ease of use, and toxicity. That GNF6702 may overcome these limitations and treats three diseases simultaneously gives great hope to the millions of people affected and millions more at risk for these diseases. 

Additional source: Genomics Institute of the Novartis Research Foundation, BBC
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
DEC 03, 2018
Cardiology
DEC 03, 2018
Alcohol Consumption: How Much Is Too Much for the Heart?
  Arteries stiffen over time as a result of aging, but heavy alcohol drinking habits over a lifetime can accelerate arterial aging, especially in men....
JUN 18, 2018
Immunology
JUN 18, 2018
Detecting and Diagnosing Rheumatoid Arthritis Before it Begins
Unique gene signatures and tiny changes in the immune system that occur in the earliest stages of rheumatoid arthritis, an autoimmune disease, could soon b...
JUN 23, 2018
Clinical & Molecular DX
JUN 23, 2018
Algorithm-Based Blood Test Diagnoses Autism
As a developmental disorder, autism spectrum disorders (ASD) can be diagnosed as early as 18 to 24 months of age, but often the diagnosis does not come unt...
AUG 16, 2018
Clinical & Molecular DX
AUG 16, 2018
Bubbles and a blood test could detect brain tumors
Researchers have developed a proof-of-concept technique that allows them to detect brain tumor biomarkers with a simple blood test, rather than a complicat...
OCT 16, 2018
Microbiology
OCT 16, 2018
Simple Test Rapidly Diagnoses Antibiotic-resistant Infections
If we get a bacterial infection, doctors use antibiotics to treat it. But sometimes people are infected by pathogens that are resistant to drugs....
OCT 29, 2018
Immunology
OCT 29, 2018
Escape of the Tumor Cell
Tumor cells in breast cancer have proven to evade the immune responses utilizing actin cytoskeleton...
Loading Comments...